Metraipolis › archive › dc_bdebc76c9380
[External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on… — Europe PMC PMID:41663184
- Source
- Europe PMC (chi)
- Original
- https://europepmc.org/article/MED/41663184
- DOI
- 10.3760/cma.j.cn121090-20250418-00188
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T04:24:36.900Z
- SHA-256 of the archived text
321fa2727a985f7362452b97975843514331de606b4ac3422474593cc48e7366- Stable URL of this page
https://metraipolis.com/documento/dc_bdebc76c9380
How to cite
[External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on… — Europe PMC PMID:41663184 — Europe PMC (chi), https://europepmc.org/article/MED/41663184 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bdebc76c9380 (Metraipolis archive dc_bdebc76c9380, sha256 321fa2727a985f7362452b97975843514331de606b4ac3422474593cc48e7366)
BibTeX
@misc{dcbdebc76c9380,
title = {[External validation and incremental value assessment of the RR6 prognostic model in Chinese myelofibrosis patients treated with ruxolitinib: focusing on… — Europe PMC PMID:41663184},
howpublished = {Europe PMC (chi)},
url = {https://europepmc.org/article/MED/41663184},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bdebc76c9380; sha256 321fa2727a985f7362452b97975843514331de606b4ac3422474593cc48e7366},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41663184. Agents can read the archived copy with the MCP tool read_document.